Literature DB >> 2111288

A proteolytic enzyme secreted by Proteus mirabilis degrades immunoglobulins of the immunoglobulin A1 (IgA1), IgA2, and IgG isotypes.

L M Loomes1, B W Senior, M A Kerr.   

Abstract

Proteus mirabilis strains associated with human urinary tract infections have previously been shown to secrete an extracellular metalloproteinase which cleaves serum immunoglobulin A (IgA). The enzyme has now been purified to apparent homogeneity from culture supernatants of P. mirabilis 64676. The protease activity is associated with a 50-kilodalton (kDa) protein. Unlike that of the classic IgA1 proteases, the substrate specificity of the P. mirabilis protease has been found to extend to both sublcasses of IgA, IgG, and the nonimmunoglobulin substrates, secretory component and casein. Cleavage of IgA1 and IgA2 by the P. mirabilis protease yielded fragments on sodium dodecyl sulfate-polyacrylamide gel electrophoresis whose sizes were consistent with a cleavage site outside the hinge region. Both secretory IgA1 and IgA2 were also cleaved by P. mirabilis protease, although the secretory IgA2 molecule was less readily cleaved than secretory IgA1. Free and IgA-bound secretory components were degraded to some extent by P. mirabilis protease. Cleavage of IgG, however, occurred at the hinge region as a two-stage process. The first stage was pepsinlike and generated an F(ab')2 fragment of 120 kDa and a small pFc fragment detected on nonreduced polyacrylamide gels. In the second stage, the F(ab')2 product was cleaved to yield papainlike Fab and Fc fragments, visualized as a diffuse band of 40 to 50 kDa.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2111288      PMCID: PMC258753          DOI: 10.1128/iai.58.6.1979-1985.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY.

Authors:  F C GREENWOOD; W M HUNTER; J S GLOVER
Journal:  Biochem J       Date:  1963-10       Impact factor: 3.857

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity.

Authors:  J H Morrissey
Journal:  Anal Biochem       Date:  1981-11-01       Impact factor: 3.365

Review 4.  Secretory immunity and the bacterial IgA proteases.

Authors:  S J Kornfeld; A G Plaut
Journal:  Rev Infect Dis       Date:  1981 May-Jun

5.  [Extracellular toxins of Pseudomonas aeruginosa. II. Effect of two proteases on human immunoglobulins IgG, IgA and secretory IgA (author's transl)].

Authors:  G Döring; H J Obernesser; K Botzenhart
Journal:  Zentralbl Bakteriol A       Date:  1981-03

Review 6.  Comparative specificity of microbial proteinases.

Authors:  K Morihara
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1974

7.  New method for obtaining IgA-specific protease.

Authors:  T B Higerd; G Virella; R Cardenas; J Koistinen; J W Fett
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

8.  Studies on gonococcus infection. XVII. IgA1-cleaving protease in vaginal washings from women with gonorrhea.

Authors:  M Blake; K K Holmes; J Swanson
Journal:  J Infect Dis       Date:  1979-01       Impact factor: 5.226

9.  Pathogenic species of the genus Haemophilus and Streptococcus pneumoniae produce immunoglobulin A1 protease.

Authors:  M Kilian; J Mestecky; R E Schrohenloher
Journal:  Infect Immun       Date:  1979-10       Impact factor: 3.441

10.  Identification and penicillinase testing of Neisseria gonorrhoeae from primary isolation cultures on modified New York City medium.

Authors:  H Young
Journal:  J Clin Microbiol       Date:  1978-03       Impact factor: 5.948

View more
  20 in total

1.  Treatment of passively transferred experimental autoimmune myasthenia gravis using papain.

Authors:  K Poulas; T Tsouloufis; S J Tzartos
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

2.  The specificity of the human neutrophil IgA receptor (Fc alpha R) determined by measurement of chemiluminescence induced by serum or secretory IgA1 or IgA2.

Authors:  W W Stewart; M A Kerr
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

3.  The specificity of the IgA receptor purified from human neutrophils.

Authors:  R L Mazengera; M A Kerr
Journal:  Biochem J       Date:  1990-11-15       Impact factor: 3.857

4.  Characterization of the immunoglobulin A protease of Ureaplasma urealyticum.

Authors:  R K Spooner; W C Russell; D Thirkell
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

Review 5.  Diversity and dynamism of IgA-microbiota interactions.

Authors:  Kelsey E Huus; Charisse Petersen; B Brett Finlay
Journal:  Nat Rev Immunol       Date:  2021-02-10       Impact factor: 53.106

Review 6.  Pathogenesis of Proteus mirabilis Infection.

Authors:  Chelsie E Armbruster; Harry L T Mobley; Melanie M Pearson
Journal:  EcoSal Plus       Date:  2018-02

7.  Analysis of human immunoglobulin-degrading cysteine proteinases of Trichomonas vaginalis.

Authors:  D Provenzano; J F Alderete
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  Molecular analysis of a metalloprotease from Proteus mirabilis.

Authors:  C Wassif; D Cheek; R Belas
Journal:  J Bacteriol       Date:  1995-10       Impact factor: 3.490

9.  Evaluation of immunoglobulin A1 (IgA1) protease and IgA1 protease-inhibitory activity in human female genital infection with Neisseria gonorrhoeae.

Authors:  S R Hedges; M S Mayo; L Kallman; J Mestecky; E W Hook; M W Russell
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

Review 10.  Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis.

Authors:  S M Jacobsen; D J Stickler; H L T Mobley; M E Shirtliff
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.